Title:
MODIFIED IMMUNE EFFECTOR CELL AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/148332
Kind Code:
A1
Abstract:
A modified immune effector cell, the immune effector cell may comprise and/or express a chimeric antigen receptor, and a BCL-2 protein or a functional active fragment thereof, and further provided is an application of the immune effector cell.
Inventors:
YANG XUANMING (CN)
WANG HAIYONG (CN)
WANG HAIYONG (CN)
Application Number:
PCT/CN2022/070012
Publication Date:
July 14, 2022
Filing Date:
January 04, 2022
Export Citation:
Assignee:
UNIV SHANGHAI JIAOTONG (CN)
International Classes:
A61K35/17; A61K39/00; A61K48/00
Domestic Patent References:
| WO2020219504A1 | 2020-10-29 |
Foreign References:
| CN110305220A | 2019-10-08 | |||
| CN111848809A | 2020-10-30 | |||
| CN108164600A | 2018-06-15 | |||
| US20160361360A1 | 2016-12-15 | |||
| US20200338128A1 | 2020-10-29 |
Other References:
WANG HAIYONG, HAN PING, QI XINYUE, LI FANLIN, LI MIN, FAN LILV, ZHANG HUIHUI, ZHANG XIAOQING, YANG XUANMING: "Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis", CANCERS, vol. 13, no. 2, 8 January 2021 (2021-01-08), pages 197, XP055857788, DOI: 10.3390/cancers13020197
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS, P.C. (CN)
Download PDF: